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Abstract
Aims: To determine whether the amount of ATP, prostaglandin E2 (PGE2),
and acetylcholine (ACh) in voided urine are influenced enough by that re-
leased within the lower urinary tract (LUT) for them to be useful biomarkers
of bladder function.
Methods: Participants without LUT symptoms collected total urine voids at
15, 30, 60, and 120min (20 males/23 females) and 240min (18 males/26 fe-
males) following the previous void. Aliquots of urine were immediately frozen
at −20°C and later used to measure ATP (luciferin‐luciferase), PGE2 (enzyme‐
linked immunosorbent assay), ACh (mass spectrometry), creatinine (colori-
metric), and lactose dehydrogenase (colorimetric).
Results: The amount of ATP in voided urine correlated strongly with the rate
of urine production, suggesting that the majority, if not all, the ATP in voided
urine has an LUT, and likely bladder, origin. In contrast, there appeared to be
no significant net LUTs release of creatinine or ACh into the urine. PGE2 was
intermediate with an LUT component that increased with urine production
rate and contributed about 25% of the total at 1 ml/min in women but a
smaller fraction in men.
Conclusion: Whereas the majority of the ATP measured within the voided
urine originates in the LUT, ACh reflects that extracted from the plasma in the
kidneys and PGE2 is a mixture of both sources. ATP has the most potential as a
biomarker of benign bladder disorders. Expressing urinary ATP concentration
relative to creatinine concentration is questioned in light of these results.
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1 | INTRODUCTION
Measuring the concentration of transmitters within the
urine as possible biomarkers of benign bladder disorders
is increasingly relevant to investigate pathological ori-
gins.1,2 ATP, prostaglandin E2 (PGE2), and acetylcholine
(ACh) are all potential candidates3,4 but to be useful as a
urinary biomarker a significant fraction of that measur-
able in the urine must have a lower urinary tract (LUT)
origin.
ATP is released in both the kidneys5 and the ur-
eters,6–9 but high levels of ectoATPases activity5,8,9 lim-
it its half‐life to only 3–4min in these areas.5 This
contrasts to 30–60min5,10 within the bladder lumen
where ectoATPases activity is lower, particularly on the
apical membrane of the umbrella cells11,12 reflecting the
lower permeability of the bladder urothelium.13–15 Thus,
it is possible that the LUT and bladder, in particular, may
contribute a significant fraction of the ATP found in
urine.
There are only a very limited number of studies
measuring urinary ACh. This is partially due to the high
levels of urinary choline that reduces the sensitivity and
accuracy of ACh detection methods, especially as ACh
itself is hydrolyzed to choline. Using mass spectrometry,
however, Kirsch et al.3 found that urinary ACh levels
were significantly higher than those in the plasma and
that they correlated strongly with plasma choline levels
in females suggesting that urine ACh levels could be
primarily determined by the amount of choline present
in the body.
Although PGE2 is known to be synthesized
throughout the urinary tract in response to stretch,
sympathetic nerve stimulation, tissue damage, or in-
flammatory mediators,16 it is unclear what fraction of the
total PGE2 in voided urine this represents. Studies in rats
where urine was sampled in the left ureter and the
bladder suggested that about half the PGE2 found in the
voided urine in rats has a bladder origin,16 but this could
be different in humans.
A significant problem with measuring the con-
centrations of any urinary biomarkers is the large
variability in the rate of urine production. Creatinine
concentration is often used to adjust for this, with the
concentrations of other substances being expressed as a
proportion. However, this presumes that other sub-
stances are handled by the urinary tract in a similar way
to creatinine, that is, that there is little or no net secretion
or reabsorption in the urinary tract, which cannot be
assumed, especially for potential markers of LUT
dysfunction.
The purpose of this study was to investigate the ex-
tent to which secretion or reabsorption of potential
biomarkers across the LUT contributes to the amount of
ATP, ACh, and PGE2 within the voided urine and how
this is affected by the rate of urine production. This has
implications for how best to compare the levels in urine
samples from different human subjects and between
samples from the same individual and whether expres-
sing their concentration relative to that of creatinine is
useful.
2 | MATERIALS AND METHODS
This study received ethical approval from the King's
College Ethics Research Committee (HR‐16/17‐3859).
Participants were students or staff members at King's
College London and all gave informed written consent
for the study. They had not taken any medication or
vitamin or mineral supplements within the previous 48 h
and all had normal bladder function as assessed using
the overactive bladder symptom bother short‐form
questionnaire (OAB‐q).17
2.1 | Urine sample collection
Participants were asked to collect the entire void at de-
signated time intervals of 15, 30, 60, 120, and 240min
while eating and drinking normally. Initially, partici-
pants were asked to give samples at all five time points
(7F/4M), but then to reduce their burden and aid re-
cruitment, they were only asked to provide samples at
the four shorter time points (16F/16M) and an additional
group gave a single 240min sample (19F/14M). Where
subjects gave more than one sample, they were assigned
a randomized order. The first void of the day was not
used for any samples.
Samples were excluded if they were ≤5ml (n= 5,
samples), there was confusion over voided volumes
(n= 4 samples), the urine production rate was very low
(≤0.25ml/min, n= 5 samples), or lactose dehydrogenase
(LDH) production rates were very high, indicative of
possible renal or urinary tract tissue damage (>7mU/
min, n= 4 participants) plus one participant with very
high creatinine concentrations (1300 ± 200mg/dl,
mean ± SD). This left a total of 208 urine samples from 76
participants, 42 females (F, 27 ± 1 years), and 34 males
(M, 28 ± 2 years).
Total void volumes were recorded and then
1 ml aliquots were frozen within 10 min and stored at
−20°C for later analysis. The rate of urine production
was calculated by dividing sample volume by the
time between voids, assuming a constant produc-
tion rate.
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2.2 | Measurement of ATP
ATP concentration was measured at room temperature in
undiluted urine samples using a luciferin‐luciferase assay
(FL‐AAM; Sigma). Urine samples were spun at 2000g for
5min and a 20 µl sample added to 20 µl of assay mix diluted
10‐fold. Luminescence was measured immediately and
ATP concentration was calculated from a standard curve
constructed for each experiment using ATP standards
(GloMax 20/20; Promega). All samples were measured in
triplicate and average values were used. Measurements
were all made well within the 3‐month storage window
identified from repeated sampling before any loss of ATP
from the samples was detected.
2.3 | Measurement of ACh
ACh was measured using mass spectrometry‐based on
the methods of Kirsch et al. 3 using a Thermo LTQ XL
mass spectrometer. Each urine sample was thawed and
10 µl added to 490 µl water and 500 µl of 10 ng/ml in-
ternal ACh standard (ACh‐D4), giving a final 100‐fold
dilution. The samples were run on a Thermo Hypersil
Gold aQ 150 × 2.1 mm 3 µm column at room tempera-
ture. The flow rate was 200 µl/min with a partial loop
injection mode and injection volume of 10 µl. The sol-
vents were 0.1% formic acid in water (Solvent A) and
0.1% formic acid in acetonitrile (Solvent B). Gradient
elution was initiated at 5% B (95% A) for 0.5 min, rising to
25% B at 3.0 min and again to 95% B at 3.5 min, main-
tained at 95% B until 5.5 min, ramped down to 5% B at
5.8 min, and held at this composition for 6.2 min giving a
12min total run time. Positive electrospray ionization
mode with a capillary voltage of 14.0 V and desolvation
gas (N2) temperature of 350°C and retention time of
~2.5 min were used to elude ACh peaks. ACh con-
centrations were calculated by reference to the internal
standard in each sample and known ACh concentrations
of 0–2500 ng/ml run at the start of each experiment.
2.4 | Measurement of PGE2
PGE2 was measured using a Prostaglandin E2 Express
ELISA Kit (500141; Cayman Chemicals) in which PGE2
in the sample competes for limited PGE2‐monoclonal
antibody bound to a 96‐well plate. Urine samples were
fully defrosted, spun at 2000g for 5 min, and diluted
sufficiently to fall into the 15.6–2000 pg/ml range of the
kit. Absorbance was measured at 405 nm and PGE2
concentration calculated using standards run in the same
plate.
2.5 | Measurement of creatinine
Creatinine concentration was measured using a colori-
metric assay kit (500701; Cayman Chemicals) run on a
96‐well plate. Urine samples were fully defrosted and
spun at 2000g for 5 min and a sample of the supernatant
diluted 5–50‐fold such that the creatinine concentration
fell within the 0–15mg/dl range of the kit. Absorbance
was measured at 490 nm and creatinine concentration
calculated using standards run in the same plate.
2.6 | Measurement of lactose
dehydrogenase LDH
LDH was measured using an LDH kit (MAK066; Sigma)
run in a 96‐well plate according to the manufacturer's
instructions. LDH activity was determined by the
amount of NADH produced from the reduction of NAD
and measured with a colorimetric assay by the absor-
bance at 450 nm, against a standard curve of known
NADH concentrations (2.5–12.5 nmol/well) run on the
same plate. LDH activity was then calculated from the
rate of production of NADH.
2.7 | Data analysis
Statistical tests (Spearman's Rank correlation and
Mann–Whitney U test) were performed as indicated in
the text or figure legends using GraphPad Prism. The
null hypothesis was rejected at p< .05.
3 | RESULTS
The rate of LDH production in urine was estimated from
one sample from each participant (mean: 2.3 ± 1.5 mU/
min, mean ± SD, n= 76). Four participants who had
values >7mU/min were identified as outliers and be-
cause this may indicate increased leakiness of the blad-
der wall, all of their samples were excluded.
The concentrations of creatinine, ATP, ACh, and
PGE2 were measured for each urine sample and
plotted as a function of the time to produce each
microliter of urine, the inverse of urine production
rate (Figure 1). Significant positive correlations were
found for creatinine, ACh, and PGE2 in both women
(red circles) and men (blue triangles). However, no
significant positive correlation was observed between
ATP concentration and time to produce each micro-
liter of urine from either women or men, indicating
that ATP concentration in the urine varies in a
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fundamentally different way to these other three
substances.
Furthermore, ATP concentration was significantly
higher in women than men [median (interquartile
range): women (n= 117), 3.6 nmol/l (2.5–5.9); men
(n= 91), 1.3 nmol/l (1.0–2.1); p< .001], which was not
the case for creatinine, ACh, or PGE2. In view of the
gender‐dependent differences in ATP concentrations, the
analysis below is shown separately for women and men.
The independence of ATP concentration from the
rate of urine production was investigated further by
measuring the amount of each substance as a function of
voided volume when collected over a single time period,
120min, in female participants (Figure 2). The amount of
creatinine measured in the urine, 120min after the pre-
vious void was independent of the void volume
(Figure 2A, r= .048, p> .05, n= 23), whereas the amount
of ATP showed a strong correlation with void volume
both across samples from multiple participants
(Figure 2B, r= .751, p< .0001, n= 23, circles) and across
samples from a single individual (one of the authors)
(Figure 2B, r= .864, p< .0001, n= 31, diamonds). ACh
and PGE2 both behaved more like creatinine than ATP in
agreement with Figure 1 (ACh: r= .280, p> .05, PGE2:
r= .296, p> .05, n= 23).
The analysis of Figure 2 using a fixed time interval
between voids can be extended to data derived from
different intervoid intervals by plotting the rate at which
a particular substance is added to the urine as a function
of the urine flow rate itself (Figure 3): note the units of
the relationships in both figures have the same units
(mol/ml). Values from samples at the five different void
time intervals are shown in different colors to allow
comparison.
If there is a constant rate of extraction of a substance
from the plasma into the urine in the kidneys with no net
secretion or absorption within the LUT, the plot in
Figure 3 should form a horizontal line with zero
FIGURE 1 Creatinine, ATP, ACh, and PGE2 concentration as a function of the time to produce each microliter of urine. Creatinine
(A), ATP (B), ACh (C), and PGE2 (D) concentration is plotted as a function of the average time in minutes for each microliter of
urine to collect (inverse of the rate of urine production). Red circles (females, n= 117 samples), and blue triangles (men, n= 91 samples).
Spearman's rank correlation r and p values are shown. ACh, acetylcholine; PGE2, prostaglandin E2
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gradients and the y‐intercept representing the rate of
entry of the substance into the urine in the kidneys. Any
dependency on urine production rate, that is, a nonzero
slope would indicate release within the LUT.
The rate of creatinine production (Figure 3A) showed
no dependency on the rate of urine production consistent
with a constant rate of release of creatinine in the kidney
and no net secretion or absorption within the LUT as
described above. In contrast, ATP (Figure 3B) showed a
strong dependency on urine production rate with an in-
tercept indistinguishable from zero. ACh (Figure 3C) was
similar to creatinine. However, the PGE2 (Figure 3D) in
the voided urine came from a mixture of that released in
the kidneys (nonzero intercept) and some released in the
LUT as indicated by a nonzero slope, the contribution of
which rose with urine production rate. Estimates from
linear fits to these data suggested that about 25% of the
total PGE2 in voided urine may come from the LUT at
urine production rates of 1 ml/min, but this would be
closer to 60% if urine production increased to 5ml/min.
Corresponding plots for male participants are shown
in Figure 4. The results were very similar to those in
women, except PGE2 dependency on urine production
rate was less obvious, suggesting a smaller component of
LUT release of PGE2 in men than women.
The concentrations of substances in urine are often
expressed relative to the concentration of creatinine to
adjust for differences in the rate of urine production.
Figure 5 shows scatter plots for the ACh, PGE2, and ATP
concentration of each sample as a function of its crea-
tinine concentration. There was a strong positive cor-
relation between ACh and PGE2 concentrations and
creatinine concentration in both women and men but
not between ATP concentration and creatinine con-
centration, as predicted from the observations above.
This severely questions the practice of expressing
FIGURE 2 The effect of void volume on the amount of creatinine, ATP, ACh, and PGE2 within the voided urine of women. Total (A)
creatinine (n= 23), (B) ATP (n= 23, circles) (additional 31 samples from one of the authors shown with diamond symbols), (C) ACh
(n= 23), and (D) PGE2 (n= 23) as a function of the void volume only for voids 120min after previously passing urine. The void interval of
120min was chosen for this analysis as a longer time interval favored a larger spread of void volumes than a shorter one and there was a
smaller time error on the 120 min time interval than the 240min one due to being part of a set of samples (mean ± SD, 122 ± 5min, n= 23,
241 ± 14min, n= 26). ACh, acetylcholine; PGE2, prostaglandin E2
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urinary ATP concentration in terms of urinary creati-
nine concentration.
4 | DISCUSSION
This is the first study to look closely at how the levels of
ATP, ACh, and PGE2 vary with urine production rate. A
possible explanation for the different dependencies of the
above substances on urine production could come from
their origins. For a substance derived from the glo-
merular filtrate, and hence the plasma, which is neither
secreted nor absorbed from the renal tubules and urinary
tract, the amount accumulating in the bladder will be
constant for a fixed period of time and the concentration
will vary according to the urine production rate. In
contrast, for a substance that is virtually absent from the
initial glomerular filtrate or which is released but sub-
sequently broken down, but then has a net secretion into
the tubular fluid or the urinary tract lumen, the amount
could vary with an increase in the final volume. In the
latter case, it is proposed that the increase in volume per
se will increase the secretion but be diluted in a greater
volume of urine such that the concentration may remain
reasonably constant. For other substances, it is possible
that a mixture of delivery from the glomerular filtrate
and some net secretion by the urinary tract may occur.
The results presented here suggest that whereas all
the creatinine and ACh measured in the voided urine is
already present when the urine enters the LUT, release of
ATP within the LUT and most likely the bladder con-
tributes the majority if not all the ATP present. PGE2 was
intermediate in that there were significant levels already
present in the urine entering the LUT, but additional
release contributed an increasing amount as urine pro-
duction rate increased, at least in women.
It is likely that the majority of the ATP that enters the
urine in the bladder comes from the urothelium, which
FIGURE 3 Rate of addition to the voided urine of creatinine, ATP, ACh, and PGE2 as a function of rate of urine production in female
participants. (A) Creatinine, (B) ATP, (C) ACh, and (D) PGE2. Urine samples at different time intervals between voids are shown as different
colored symbols, 15 min (red), 30 min (orange), 60 min (blue), 120min (green), and 240min (black). Mean slopes (±SD) from best fit linear
fits were (mol/min) creatinine, −0.02 ± 0.04; ATP, 0.5 ± 0.2; ACh, 0.1 ± 0.1; and PGE2 0.2 ± 0.1, intercepts were (mol/min)
creatinine, 1.4 ± 0.3; ATP, −0.1 ± 0.4; ACh, 0.6 ± 0.3; and PGE2, 0.6 ± 0.1. Bold values were significantly nonzero. ACh, acetylcholine;
PGE2, prostaglandin E2
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itself constitutes about 60%–75% of the total amount of
ATP released in the bladder.18 ATP concentration was
found to be very dependent on the rate of urine pro-
duction, which we assume relates to the rate of bladder
stretch. This fits well with observations from in vitro
experiments where bladder strips have been shown to
release significantly more ATP following stretching than
in a resting state.19 Indeed, the amount of urothelial ATP
release has been closely linked to the speed, magnitude,
and direction of stretch.11,20 The increased ATP produc-
tion at higher rates of urine production has also been
seen by others in patients who gave two urine samples,
one after water‐loading.4 Also, in cystoscopy studies that
measure whole bladder release directly, Cheng et al.21
found ATP levels up to 60 nM, 5–10 times higher than
those seen physiologically, when using a very high
bladder filling rate (75ml/min).
The lack of correlation of ATP concentration with
that of creatinine is not unexpected given the observation
that creatinine is released at a constant rate, but ATP is
dependent on the amount of bladder stretch. A lack of
correlation has also been reported by others.22 This does,
however, question the value of expressing urinary ATP
concentrations in terms of creatinine concentration or
any other marker of dilution rather than the rate of urine
production.
Urinary ACh appeared to be predominantly de-
termined by the amount of ACh extracted from the
plasma in the kidneys. This fits well with reports of a
high level of correlation between urinary ACh and
plasma choline levels in females, suggesting that urine
ACh levels could be influenced primarily by the amount
of choline present in the body.3
Our results suggest that although there is some LUT
component to the total voided PGE2, it is less than that of
ATP. We estimate that LUT release is unlikely to contribute
more than about a third of the total at normal filling rates,
although the percentage will increase with greater
FIGURE 4 Rate of addition to the voided urine of creatinine, ATP, ACh, and PGE2 as a function of rate of urine production in male
participants. (A) Creatinine, (B) ATP, (C) ACh, and (D) PGE2. Urine samples at different time intervals between voids are shown as
different colored symbols, 15 min (red), 30 min (orange), 60 min (blue), 120 min (green), and 240min (black). Mean slopes (±SD) from best
fit linear fits were (mol/min) creatinine, 0.06 ± 0.08; ATP, 0.3 ± 0.2; ACh, 0.04 ± 0.04; and PGE2, 0.06 ± 0.08, intercepts were (mol/min)
creatinine, 2.0 ± 0.3; ATP, −0.2 ± 0.3; ACh, 0.8 ± 0.1; and PGE2, 1.3 ± 0.2. Bold values were significantly nonzero. ACh, acetylcholine;
PGE2, prostaglandin E2
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hydration. It is likely that, as in the case of ATP, more of
the PGE2 released by the urothelium than other layers will
reach the urine. It is unclear why this was only seen in the
females but may reflect an effect not seen with the slightly
smaller number of male samples, a proportionally larger
constant rate of release in the males or a difference in
bladder properties. Given that the bladder ATP release was
also significantly lower in men than women, it could be a
genuine difference in stretching properties of the bladder,
although despite male bladders being shown to have a
thicker detrusor than those of women,23 gender differences
in contractility have not been seen.24
5 | LIMITATIONS
The biggest problem in this study was that participants
tended to drink more when doing the shorter interval
samples than the longer ones. This initially led us to
think that ATP levels were higher at shorter times be-
tween voids,25 but although a small effect of time be-
tween voids cannot be ruled out, we now believe that this
difference can be fully explained by the difference in the
rate of urine production.
Participants were asked to collect the whole void
and then to tip a sample from that into a tube for
analysis. Collecting the whole void meant that in
smaller samples, there was a risk of contamination.
We did not, however, want to risk asking participants
to collect a mid‐stream sample while filling the jug as
this may have compromised the accuracy of the vo-
lume measured if the sample was lost, spilt, or the
tube content was missed from the total, for example.
To reduce the risks of contamination, only samples of
5 ml or more were included.
6 | CONCLUSIONS
The LUT contributes the majority of the ATP found in
the voided urine and up to about a third of the PGE2
in women but little or none of the creatinine and ACh.
ATP represents a better potential biomarker of blad-
der function than ACh and PGE2 and sensitivity could
be improved by water loading. The commonly used
practice of expressing urine ATP concentration as a
function of creatinine concentration is questioned in
the light of these results.
FIGURE 5 ACh, PGE2, and ATP concentration as a function of creatinine concentration. (A–C) Females (n= 117), (D–F) males
(n= 91). Spearman's rank correlation r and p values are shown for each graph. There was a significant positive correlation between ACh and
PGE2 and creatinine concentrations but not ATP. ACh, acetylcholine; PGE2, prostaglandin E2
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